proteomic analysis active multiple sclerosis lesions reveals therapeutic targets 
understanding neuropathology multiple sclerosis ms essential improved therapies therefore identification targets specific pathological types ms may therapeutic benefits identify laser capture microdissection proteomics proteins unique three major types ms lesions: acute plaque chronic active plaque chronic plaque comparative proteomic profiles identified tissue factor protein c inhibitor within chronic active plaque samples suggesting dysregulation molecules associated coagulation vivo administration hirudin recombinant activated protein c reduced disease severity experimental autoimmune encephalomyelitis suppressed th1 th17 cytokines astrocytes immune cells administration mutant forms recombinant activated protein c showed anticoagulant signalling functions essential optimal amelioration experimental autoimmune encephalomyelitis proteomic approach illuminated potential therapeutic targets selective specific pathological stages ms implicated participation coagulation cascade 
